Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

References

• GBD 2017 Causes of death collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10. 2017;392(10159):1736–1788.
   Web of Science ®Google Scholar
• Global Burden of Cardiovascular Diseases Collaboration, Roth GA, Johnson CO, Abate KH, et al. The burden of cardiovascular diseases among US States, 1990-2016. JAMA Cardiol. 2018 May 1;3(5):375–389.
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139–e596.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381.
   Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019 Sep 10;74(10):e177-e232.
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 Jan 30;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013 Jan 29;61(4):427–436.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013 Jun;34(24):1826–1833.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR variants with risk of coronary heart disease. JAMA. 2019 Jan 29;321(4):364–373.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Haynes R, Hopewell JC, et al. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018 Jul 17;72(3):330–343.
   PubMed Web of Science ®Google Scholar
• Di CM, Bentham J, Stevens GA, et al. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016 Apr 2;387(10026):1377–1396.
   PubMed Web of Science ®Google Scholar
• Justesen JM, Allin KH, Sandholt CH, et al. Interactions of lipid genetic risk scores with estimates of metabolic health in a danish population. Circ Cardiovasc Genet. 2015 Jun;8(3):465–472.
   PubMedGoogle Scholar
• Ali A, Varga TV, Stojkovic IA, et al. Do genetic factors modify the relationship between obesity and Hypertriglyceridemia? Findings from the GLACIER and the MDC Studies. Circ Cardiovasc Genet. 2016 Apr;9(2):162–171.
   PubMedGoogle Scholar
• Sinclair HM. Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet. 1956 Apr 7;270(6919):381–383.
   PubMedGoogle Scholar
• Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200(1–6):69–73.
   PubMedGoogle Scholar
• Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr. 1980 Dec;33(12):2657–2661.
   PubMed Web of Science ®Google Scholar
• Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971 Jun 5;297(7710):1143–1145.
   Web of Science ®Google Scholar
• Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand. 1972 Jul-Aug;192(1–6):85–94.
   PubMedGoogle Scholar
• Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975 Sep;28(9):958–966.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Hjorne N. Plasma cholesterol concentration in Caucasian Danes and Greenland West-coast Eskimos. Dan Med Bull. 1977 Apr;24(2):52–55.
   PubMedGoogle Scholar
• Miller GJ, Koplan JP, Morgan P, et al. High-density lipoprotein cholesterol concentration and other serum lipids in an isolated island community free of coronary heart disease. Int J Epidemiol. 1979 Sep;8(3):219–225.
   PubMed Web of Science ®Google Scholar
• Kagawa Y, Nishizawa M, Suzuki M, et al. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol (Tokyo). 1982;28(4):441–453.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979 Sep 1;28(8140):433–435.
   Google Scholar
• Hirai A, Hamazaki T, Terano T, et al. Eicosapentaenoic acid and platelet function in Japanese. Lancet. 1980 Nov 22;2(8204):1132–1133.
   PubMed Web of Science ®Google Scholar
• Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985 May 9;312(19):1205–1209.
   PubMed Web of Science ®Google Scholar
• Keli SO, Feskens EJ, Kromhout D. Fish consumption and risk of stroke. The Zutphen Study. Stroke. 1994 Feb;25(2):328–332.
   PubMed Web of Science ®Google Scholar
• Orencia AJ, Daviglus ML, Dyer AR, et al. Fish consumption and stroke in men. 30-year findings of the Chicago Western ElectricStudy. Stroke. 1996 Feb;27(2):204–209.
   PubMed Web of Science ®Google Scholar
• Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997 Apr 10;336(15):1046–1053.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747–2757.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011 Nov 8;58(20):2047–2067.
   PubMed Web of Science ®Google Scholar
• Harris WS. N-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr. 1997 May;65(5):1645S–1654S.
   PubMed Web of Science ®Google Scholar
• Goyens PL, Mensink RP. Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects. Eur J Clin Nutr. 2006 Aug;60(8):978–984.
   PubMed Web of Science ®Google Scholar
• Egert S, Kannenberg F, Somoza V, et al. Dietary alpha-linolenic Acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr. 2009 May;139(5):861–868.
   PubMed Web of Science ®Google Scholar
• Rivellese AA, Maffettone A, Iovine C, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care. 1996 Nov;19(11):1207–1213.
   PubMed Web of Science ®Google Scholar
• Faeh D, Minehira K, Schwarz JM, et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005 Jul;54(7):1907–1913.
   PubMed Web of Science ®Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006 Aug;17(4):387–393.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006 Aug 21;98(4):27i–33i.
   PubMedGoogle Scholar
• Hein GJ, Bernasconi AM, Montanaro MA, et al. Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids. Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E429–39.
   PubMed Web of Science ®Google Scholar
• Sato A, Kawano H, Notsu T, et al. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes. 2010 Oct;59(10):2495–2504.
   PubMed Web of Science ®Google Scholar
• Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care. 2011 Mar;14(2):115–120.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978 Jul 15;2(8081):117–119.
   PubMed Web of Science ®Google Scholar
• Fischer S, Weber PC. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983 Nov 15;116(3):1091–1099.
   PubMed Web of Science ®Google Scholar
• Fischer S, Weber PC. Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature. 1984 Jan 12-18;307(5947):165–168.
   PubMed Web of Science ®Google Scholar
• Hornstra G, Haddeman E, ten Hoor F. Fish oils, prostaglandins, and arterial thrombosis. Lancet. 1979 Nov 17;2(8151):1080.
   PubMed Web of Science ®Google Scholar
• Siess W, Roth P, Scherer B, et al. Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet. 1980 Mar 1;1(8166):441–444.
   PubMed Web of Science ®Google Scholar
• Goodnight SH Jr, Harris WS, Connor WE, et al. Polyunsaturated fatty acids, hyperlipidemia, and thrombosis. Arteriosclerosis. 1982 Mar-Apr;2(2):87–113.
   PubMedGoogle Scholar
• Hornstra G, Haddeman E, Kloeze J, et al. Dietary-fat-induced changes in the formation of prostanoids of the 2 and 3 series in relation to arterial thrombosis (rat) and atherosclerosis (rabbit). Adv Prostaglandin Thromboxane Leukot Res. 1983;12:193–202.
   PubMedGoogle Scholar
• Nelson JR, True WS, Le V, et al. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med. 2017 Nov;129(8):822–827.
   PubMed Web of Science ®Google Scholar
• Mason RP. New insights into mechanisms of action for Omega-3 Fatty Acids in Atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019 Jan 12;21(1):2–019-0762-1.
   Web of Science ®Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020 May;40(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Lefils-Lacourtablaise J, Socorro M, Geloen A, et al. The Eicosapentaenoic Acid Metabolite 15-Deoxy-delta(12,14)-Prostaglandin J3 Increases Adiponectin Secretion by Adipocytes Partly via a PPARgamma-Dependent Mechanism. PLoS One. 2013 May 29;8(5):e63997.
   PubMed Web of Science ®Google Scholar
• Yamada H, Kikuchi S, Hakozaki M, et al. 8-Hydroxyeicosapentaenoic Acid Decreases Plasma and Hepatic Triglycerides via Activation of Peroxisome Proliferator-Activated Receptor Alpha in High-Fat Diet-Induced Obese Mice. J Lipids. 2016;2016:7498508.
   PubMed Web of Science ®Google Scholar
• Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. Curr Opin Cardiol. 2019 Nov;34(6):721–727.
   PubMed Web of Science ®Google Scholar
• Wang C, Harris WS, Chung M, et al. N−3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: A systematic review. Am J Clin Nutr. 2006 Jul;84(1):5–17.
   PubMed Web of Science ®Google Scholar
• Alexander DD, Miller PE, Van Elswyk ME, et al. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017 Jan;92(1):15–29.
   PubMed Web of Science ®Google Scholar
• Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiol. 2018 Mar 1;3(3):225–234.
   PubMed Web of Science ®Google Scholar
• Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Feb;29(3):CD003177.
   Google Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999 Aug 7;354(9177):447–455.
   PubMed Web of Science ®Google Scholar
• Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019 Jan 3;380(1):33–44.
   PubMed Web of Science ®Google Scholar
• Pan A, Chen M, Chowdhury R, et al. Alpha-Linolenic acid and risk of cardiovascular disease: A systematic review and meta-analysis. Am J Clin Nutr. 2012 Dec;96(6):1262–1273. .
   PubMed Web of Science ®Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis. Curr Atheroscler Rep. 2011 Dec;13(6):474–483.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Glickstein SB, Rowe JD, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. J Clin Lipidol. 2012 Jan-Feb;6(1):5–18.
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. J Atheroscler Thromb. 2012;19(7):673–679.
   PubMed Web of Science ®Google Scholar
• Singh S, Arora RR, Singh M, et al. Eicosapentaenoic acid versus docosahexaenoic acid as options for vascular risk prevention: A fish story. Am J Ther. 2016 May-Jun;23(3):e905–10.
   PubMed Web of Science ®Google Scholar
• Asztalos IB, Gleason JA, Sever S, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: A randomized clinical trial. Metabolism. 2016 Nov;65(11):1636–1645.
   PubMed Web of Science ®Google Scholar
• Yang ZH, Amar M, Sampson M, et al. Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich fish oil supplementation on plasma lipids and Lipoproteins in Normolipidemic Adults. Nutrients. 2020 Mar 12;12(3):749.
   Web of Science ®Google Scholar
• Fialkow J. Omega-3 fatty acid formulations in cardiovascular disease: Dietary supplements are not substitutes for prescription products. Am J Cardiovasc Drugs. 2016 Aug;16(4):229–239.
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Wiggins BS, Bottorff MB. Critical differences between dietary supplement and prescription omega-3 Fatty Acids: A narrative review. Adv Ther. 2020 Feb;37(2):656–670.
   PubMed Web of Science ®Google Scholar
• Qato DM, Wilder J, Schumm LP, et al. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016 Apr;176(4):473–482.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Rehm CD, Du M, et al. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016 Oct 11;316(14):1464–1474.
   PubMed Web of Science ®Google Scholar
• Cohen PA. The supplement paradox: Negligible benefits, robust consumption. JAMA. 2016 Oct 11;316(14):1453–1454.
   PubMed Web of Science ®Google Scholar
• Cohen PA. Hazards of Hindsight — monitoring the safety of nutritional supplements. N Engl J Med. 2014 Apr 3;370(14):1277–1280.
   PubMed Web of Science ®Google Scholar
• Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015 Oct 15;373(16):1531–1540.
   PubMed Web of Science ®Google Scholar
• Collins N, Tighe AP, Brunton SA, et al. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: A legislative and regulatory perspective. J Am Coll Nutr. 2008 Dec;27(6):659–666.
   PubMed Web of Science ®Google Scholar
• Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013 Jun;93(8):1935–1939.
   PubMed Web of Science ®Google Scholar
• Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015 Apr;95(6):1260–1267.
   PubMed Web of Science ®Google Scholar
• Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015 Jan 21;5(1):7928.
   PubMedGoogle Scholar
• Jackowski SA, Alvi AZ, Mirajkar A, et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci. 2015 Nov 4;4:e30.
   PubMed Web of Science ®Google Scholar
• Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun. 2017 Jan 29;483(1):425–429.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar 31;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135–140.
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Miyamoto T, Miyasita T, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)—Rationale and design. J Cardiol. 2014 Sep;64(3):236–239.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017 Dec;70(6):537–544.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682–690.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012 Oct 1;110(7):984–992.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb;13(1):37–46.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar;40(3):138–148.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Stroes ESG. FISHing for the Miracle of Eicosapentaenoic Acid. N Engl J Med. 2019 Jan 3;380(1):89–90.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M. Cardiovascular Risk Reduction with Icosapent Ethyl. Reply. N Engl J Med. 2019 Apr 25;380(17):1678.
   PubMed Web of Science ®Google Scholar
• Bhatt DL. REDUCE-IT. Eur Heart J. 2019 Apr 14;40(15):1174–1175.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: from REDUCE-IT. J Am Coll Cardiol. 2019 Jun 11;73(22):2791–2802.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 Feb 4;141(5):367–375.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019 Aug 27;74(8):1159–1161.
   PubMed Web of Science ®Google Scholar
• Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019 Nov - Dec;13(6):860–872.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl1):S111–S134.
   PubMedGoogle Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Jan;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA News Release: FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. December 13, 2019; Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups. Cited 2020 May 20
   Google Scholar
• Health Canada. Notice: Prescription Drug List (PDL): multiple additions. February 13, 2020; Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/multiple-additions-2020-02-13.html. Cited 2020 May 20
   Google Scholar
• European Medicines Agency. EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack. March 29, 2019; Available at: https://www.ema.europa.eu/en/news/ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after. Cited 2020 May 20
   Google Scholar
• Budoff M, Brent Muhlestein J, Le VT, et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol. 2018 Jan;41(1):13–19.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of Icosapent Ethyl on progression of coronary atherosclerosis in patients with elevated Triglycerides on Statin Therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim Results. Cardiovasc Res. 2021 Mar 21;117(4):1070-1077.
   Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: Final results of the EVAPORATE trial. Eur Heart J. 2020 Oct 21;41(40):3925–3932.
   PubMed Web of Science ®Google Scholar
• UMIN-CTR Clinical Trial. Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid. April 27, 2018; Available at: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014051. Cited 2020 May 20
   Google Scholar
• Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct;41(10):1281–1288.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA. 2020 Dec 8;324(22):2268–2280.
   PubMed Web of Science ®Google Scholar
• Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 Fatty Acid supplements in elderly patients after myocardial infarction: A randomized, controlled trial. Circulation. 2021 Feb 9;143(6):528–539.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 Dec;206:80–93.
   PubMed Web of Science ®Google Scholar
• Laake K, Myhre P, Nordby LM, et al. Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. BMC Geriatr. 2014 Jun 13;14(1):74.
   PubMedGoogle Scholar
• Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory from the American Heart Association. Circulation. 2019 Sep 17;140(12):e673–e691.
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Bhatt DL, Zhang Z, et al. Cost-effectiveness of icosapent ethyl in US REDUCE-IT patients. 2020; Available at: https://www.onlinejacc.org/content/75/11_Supplement_1/1914. Cited 2020 Sept 17
   Google Scholar
• Bhatt DL, Briggs AH, Reed SD, et al. Cost-Effectiveness of Alirocumab in patients with acute coronary syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 May 12;75(18):2297–2308.
   PubMed Web of Science ®Google Scholar
• Jia X, Akeroyd JM, Nasir K, et al. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 Mar 5;139(10):1341–1343.
   PubMed Web of Science ®Google Scholar
• Picard F, Bhatt DL, Ducrocq G, et al. Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. J Am Coll Cardiol. 2019 Mar 26;73(11):1362–1364.
   PubMed Web of Science ®Google Scholar
• Case BC, Bress AP, Kolm P, et al. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. J Clin Lipidol. 2019 Sep - Oct;13(5):754–761.
   PubMed Web of Science ®Google Scholar